Study population We implemented two active comparator, new user cohorts.26 The first cohort was composed of patients who started and continued on either a GLP-1 receptor agonist (dulaglutide, exenatide, liraglutide (except the 3 mg/0.5 mL formulation indicated for weight loss), lixisenatide, semaglutide) or a DPP-4 inhibitor (alogliptin, linagliptin, saxagliptin, sitagliptin, vildagliptin) for the first time between 1 January 2007 (the year these medications entered the UK market) and 31 December 2020
Semaglutide has demonstrated beneficial cardiovascular and anti-inflammatory effects and has been shown to have effects relevant to AD in non-clinical models
However, for people with pre-existing gastroparesis (a condition where the stomach takes too long to empty food), semaglutide can make symptoms worse
Failing to follow up on lab test results If a doctor fails to order the appropriate tests, misses key symptoms, or fails to act on test results, this opens the door for a medical malpractice claim